TY - CHAP M1 - Book, Section TI - ANTITHROMBOTIC THERAPY FOR VALVULAR HEART DISEASE A1 - Bahl, Vinay K. A1 - Math, Ravi S. A2 - Fuster, Valentin A2 - Harrington, Robert A. A2 - Narula, Jagat A2 - Eapen, Zubin J. PY - 2017 T2 - Hurst's The Heart, 14e AB - The worldwide burden of valvular heart disease (VHD) continues to grow as a result of increases in life expectancy combined with the high incidence of rheumatic heart disease in developing nations.1 Patients with VHD and certain comorbid conditions or prosthetic heart valves (PHVs) are at high risk for thromboembolic complications and often require antithrombotic therapy (Table 53–1). Although bleeding is a risk with all antithrombotic agents, the frequency and consequences of a stroke make drug therapy appropriate in many patients with VHD.2 SN - PB - McGraw-Hill Education CY - New York, NY Y2 - 2024/03/28 UR - accesscardiology.mhmedical.com/content.aspx?aid=1161731957 ER -